Citadel Advisors’s Bone Biologics Corp Warrants BBLGW Stock Holding History

Citadel Advisors’s Portfolio BBLGW Stock Details BBLGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$684K	Sell	29,752 -5,571	-16%	-$132K	﹤0.01%	8536
2025 Q4	$548K	Sell	35,323 -250	-0.7%	-$3.87K	﹤0.01%	8814
2025 Q3	$356K	Sell	35,573 -100	-0.3%	-$1.06K	﹤0.01%	9951
2025 Q2	$535K	Sell	35,673 -3	-0%	-$45	﹤0.01%	8471
2025 Q1	$557K	Buy	35,676 +921	+3%	+$55.7K	﹤0.01%	8252
2024 Q4	$1.48M	Sell	34,755 -1,996	-5%	-$58.1K	﹤0.01%	6267
2024 Q3	$1.82M	Sell	36,751 -9	-0%	-$603	﹤0.01%	5719
2024 Q2	$2.02M	Buy	36,760 +3,723	+11%	+$95.7K	﹤0.01%	5287
2024 Q1	$568K	Buy	+33,037	New	+$364K	﹤0.01%	8099
2023 Q4	–	Sell	-24,329	Closed	-$324K	–	14261
2023 Q3	$324K	Buy	+24,329	New	+$119K	﹤0.01%	9024

Other funds holding BBLGW

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BBLGW Position: Q1 2026 in Review

Citadel Advisors reduced its Bone Biologics Corp Warrants (BBLGW) stake by 16% in Q1 2026, selling an estimated $132K and leaving 29,752 shares worth $684K. The position accounts for ﹤0.01% of the portfolio, ranked #8536.

Citadel Advisors first reported a position in BBLGW in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.02M in Q2 2024. 2 funds tracked by Wall St. Rank hold BBLGW as of Q1 2026.

Citadel Advisors held 29,752 shares of Bone Biologics Corp Warrants worth $684K as of Q1 2026.
Citadel Advisors sold 5,571 Bone Biologics Corp Warrants shares in Q1 2026, an estimated $132K.
Bone Biologics Corp Warrants made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8536 holding.
Citadel Advisors first reported a position in Bone Biologics Corp Warrants in Q3 2023 and has held it in 10 quarters since.
Citadel Advisors's Bone Biologics Corp Warrants position peaked at $2.02M in Q2 2024.
2 funds tracked by Wall St. Rank held Bone Biologics Corp Warrants as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.